June 9, 2022
Life Sciences
  • The White House announced that it is shifting some of its COVID-19 funding to invest more in vaccines and the antiviral treatment Paxlovid. The administration will divert a total of $10 billion from testing and personal protective equipment – $5 billion will go towards buying updated vaccines for the fall, $4.9 billion will go towards buying an additional 10 million courses of Paxlovid, and $300 million will go to buying more monoclonal antibody treatments. The reallocation comes after Congress failed to pass additional COVID-19 funding. (Articles here, here, and here)